Company: MYGN
Filing Date: 2025-04-09
Form Type: DEF 14A
Source: 0000899923-25-000028
Chunk: 24

Company: MYRIAD GENETICS INC
Filing Date: 2025-04-09
Form: DEF 14A
Chunk 24
---
 have resulted in the addition of four new independent directors over the past five years, including the appointment of Mr. Bisaro in October 2022 and Mr. Davis in December 2024.

On February 24, 2025, Mr. Diaz resigned from his positions as President and Chief Executive Officer and as a member of the Board, effective April 30, 2025, and was therefore not nominated for re-election at the 2025 Annual Meeting by the Board. Subsequently, the Board appointed Mr. Raha as President and Chief Executive Officer and as a Class II Director to fill the vacancy on the Board that will be created by Mr. Diaz's resignation, in each case effective April 30, 2025, As part of the Mr. Raha's appointment as President and Chief Executive Officer, we agreed to nominate Mr. Raha for re-election to the Board for any succeeding term or terms as a Board member that commence during the term of his employment. The Board accepted the recommendation of the NGC and unanimously resolved to nominate Heiner Dreismann, Ph.D., Samraat S. Raha, and Colleen F. Reitan for election at the Annual Meeting as Class II Directors to serve until the 2028 Annual Meeting of Stockholders, and until their successors have been elected and qualified, or until his or her earlier death, resignation, retirement or removal.

Set forth below in the table and biographies are the names of the persons nominated as directors and the current directors of the Company, their ages as of April 8, 2025, their offices in the Company, if any, their principal occupations or employment for at least the past five years, the length of their tenure as directors and the names of other public companies in which such persons currently hold directorships or have held directorships in the past five years. Additionally, information about the specific experience, qualifications, attributes or skills that led to the Board’s conclusion at the time of the filing of this proxy statement that each person listed below should serve as a director is set forth below for each individual director.

11

| Name and Position                                                          |     | Age |     | Audit and Finance Committee |     | Compensation and Human Capital  Committee |     | Nominating and Governance Committee |     | Research and Product Innovation Committee |
| S. Louise Phanstiel                                                        
 Chair of the Board                                                         |     |  66 |     |                             |     |                                           |     |                                     |     |                                           |
| Paul J.